CALAN SR (verapamil hydrochloride) by Pfizer is mechanism of action essential hypertension verapamil exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/min) is uncommon (1. First approved in 1986.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
CALAN SR is an extended-release oral formulation of verapamil hydrochloride, a calcium channel blocker that reduces systemic vascular resistance and dilates coronary arteries. It treats essential hypertension, angina (including vasospastic/Prinzmetal's angina), and certain arrhythmias by inhibiting calcium influx through slow channels. The mechanism decreases heart rate, prolongs AV node conduction, and reduces cardiac workload.
Declining claims and imminent loss of exclusivity signal a shrinking commercial footprint; brand teams are typically small and focused on defensive tactics or transition planning.
Mechanism of action Essential hypertension Verapamil exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/min) is uncommon (1.4%). During isometric or dynamic…
Worked on CALAN SR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCareer roles on CALAN SR are primarily defensive and maintenance-focused, centered on maximizing existing patient adherence and managing generic transition. This product offers limited growth opportunity but provides solid experience in mature product stewardship, payer negotiations, and managed care strategy.